Cathie Wood Sells $12.8 Million Of Alphabet, Days After The Stock Suffered Its Worst Day Since Its 2004 IPO, Losing Nearly Half A Trillion Dollars In Market Value
ARK Invest sold $12.8 million in Alphabet shares on Nov. 4 and $3.5 million on Nov. 3, following Alphabet's worst day as a public company. Alphabet's Q3 revenue missed estimates, with search revenue below expectations. ARK also sold shares in Eli Lilly and Amazon, and bought Nurix Therapeutics. Alphabet's stock is down 12.81% since its Oct. 28 close.
How this was made
The 30-second read
Why it matters
Fund activity signals shifting confidence among large‑cap tech and biotech sectors, with possible short‑term price pressure on Alphabet and neutral impact on the other names.
Market read
ARK’s reduction of its Alphabet stake after a historic loss may influence tech‑sector sentiment, while its new biotech position underscores continued AI‑related investment themes.
What to watch
Potential longer‑term AI spending and cloud growth may offset short‑term sell pressure.
Background
ARK Invest disclosed its daily trades, highlighting reductions in its holdings of Alphabet, Eli Lilly, and Amazon, and a new position in Nurix Therapeutics.
Ticker impact
ARK Invest sold 46,164 shares of Alphabet for $12.8 million, following the stock’s worst‑day loss of about $482 billion.
likely downward pressure as investors react to fund disinvestment
Fund sales after a massive one‑day loss suggest reduced confidence and may trigger further selling.
ARK also sold 8,551 Eli Lilly shares for $12.1 million, despite Lilly’s 29.7% YTD gain and raised 2026 revenue guidance.
limited effect, likely neutral to slight downside
A modest fund sale amid strong performance is unlikely to move the stock materially.
ARK sold 15,750 Amazon shares for $4.2 million as part of the same trading day.
no meaningful price change expected
The trade size is trivial relative to Amazon’s market cap.
ARK bought 350,410 Nurix Therapeutics shares for $9.0 million, despite the biotech’s 38% intraday drop.
possible modest upside as fund buying may signal confidence
Fund purchase can provide support for a volatile biotech, but trial risk remains.
Market effects
The fund’s sell‑off in Alphabet may pressure other large‑cap tech names, while the buy in Nurix highlights continued interest in AI‑related biotech.
U.S. equity markets could see modest downside pressure in the tech sector.
Limited to U.S. markets; no direct global macro effect.
Counterpoint
The sell‑off could be a buying opportunity if the price dip is over‑reacted.
Key entities
- PersonCathie Wood
Founder of ARK Invest, whose fund actions drive the reported trades.
- CompanyAlphabet Inc.
Parent of Google, experienced a record one‑day market‑value loss.
